1416 / 1835
Pembrolizumab is highly effective in heavily pre-
treated HL patients
Patients
31
Age
32 (20-67)
Sex
M 58%
F 42%
Histology
NS 97%
MC 3%
Bulky disease
6%
Prior Tx
5+ 55%
Prior BV
100%
Prior auto-SCT
71%
ORR
65%
CR
16%
PR
48%
Ansell et al,
J Clin Oncol
2016